Mereo BioPharma Group vs Scienture
Mereo BioPharma Group reported revenue of $0 million in fiscal 2025, 1.2 times Scienture's $0 million in fiscal 2025. Mereo BioPharma Group had an operating margin of -8021.4%, against -9867.9% at Scienture.
Side by side
| Mereo BioPharma Group | Scienture | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $0M | $0M |
| Revenue growth | — | 215.9% |
| Revenue growth a year, last 5 years | — | −52.8% |
| Gross margin | — | 76.8% |
| Operating margin | −8,021.4% | −9,867.9% |
| Net margin | −8,375.6% | −9,618.0% |
| Free cash flow | −$31M | — |
| Free cash flow margin | −6,198.2% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 7.8% | 320.1% |
| Last close | $0.28 | $2.44 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | 4 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Mereo BioPharma GroupScienture
Operating margin
Percent of revenue
Mereo BioPharma GroupScienture
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Mereo BioPharma GroupScienture
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Mereo BioPharma Group and Scienture pages.